XML 52 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Revision of Previously Issued Quarterly Financial Statements - Schedule of Error Corrections and Prior Period Adjustments (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2022
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]              
Additional paid-in capital           $ 451,608 $ 432,831
Accumulated deficit           (457,484) (420,976)
Statement of Operations and Comprehensive Loss [Abstract]              
Research and development expenses           18,583 13,778
Selling, general and administrative expenses           17,303 13,637
Total operating expenses           35,886 27,415
Operating loss           (33,853) (24,531)
Net loss           (36,508) (25,649)
Total other comprehensive loss           $ (36,407) $ (25,527)
Basic loss per common share*           $ (4.12) $ (3.59)
Diluted loss per common share*           $ (4.12) $ (3.59)
Statement of Stockholders' Equity [Abstract]              
Compensation expense for issuance of stock options           $ 7,941 $ 7,832
Net loss           (36,508) (25,649)
Statement of Cash Flows [Abstract]              
Net loss           (36,508) (25,649)
Stock option compensation expense           $ 7,941 $ 7,832
Previously Reported [Member]              
Statement of Financial Position [Abstract]              
Additional paid-in capital $ 442,066 $ 435,922 $ 434,305 $ 435,922 $ 442,066    
Accumulated deficit (447,341) (438,836) (429,179) (438,836) (447,341)    
Statement of Operations and Comprehensive Loss [Abstract]              
Research and development expenses 3,953 5,456 4,240 9,696 13,649    
Selling, general and administrative expenses 4,519 4,145 3,648 7,791 12,309    
Total operating expenses 8,472 9,601 7,888 17,487 25,958    
Operating loss (7,801) (8,984) (7,543) (16,527) (24,327)    
Net loss (8,505) (9,657) (8,203) (17,860) (26,365)    
Total other comprehensive loss $ (8,551) $ (9,688) $ (8,201) $ (17,889) $ (26,447)    
Basic loss per common share* $ (0.92) $ (1.18) $ (1) $ (2.18) $ (3.09)    
Diluted loss per common share* $ (0.92) $ (1.18) $ (1) $ (2.18) $ (3.09)    
Statement of Stockholders' Equity [Abstract]              
Compensation expense for issuance of stock options $ 1,255 $ 1,617 $ 1,474        
Net loss (8,505) (9,657) (8,203) $ (17,860) $ (26,365)    
Statement of Cash Flows [Abstract]              
Net loss (8,505) (9,657) (8,203) (17,860) (26,365)    
Stock option compensation expense     1,474 3,091 4,345    
Revision of Prior Period, Adjustment [Member]              
Statement of Financial Position [Abstract]              
Additional paid-in capital 1,671 1,299 797 1,299 1,671    
Accumulated deficit (1,671) (1,299) (797) (1,299) (1,671)    
Statement of Operations and Comprehensive Loss [Abstract]              
Research and development expenses 112 150 241 391 503    
Selling, general and administrative expenses 260 352 556 908 1,168    
Total operating expenses 372 502 797 1,299 1,671    
Operating loss (372) (502) (797) (1,299) (1,671)    
Net loss (372) (502) (797) (1,299) (1,671)    
Total other comprehensive loss $ (372) $ (502) $ (797) $ (1,299) $ (1,671)    
Basic loss per common share* $ (0.04) $ (0.06) $ (0.1) $ (0.16) $ (0.2)    
Diluted loss per common share* $ (0.04) $ (0.06) $ (0.1) $ (0.16) $ (0.2)    
Statement of Stockholders' Equity [Abstract]              
Compensation expense for issuance of stock options $ 372 $ 502 $ 797        
Net loss (372) (502) (797) $ (1,299) $ (1,671)    
Statement of Cash Flows [Abstract]              
Net loss (372) (502) (797) (1,299) (1,671)    
Stock option compensation expense     797 1,299 1,671    
As Revised [Member]              
Statement of Financial Position [Abstract]              
Additional paid-in capital 443,737 437,221 435,102 437,221 443,737    
Accumulated deficit (449,012) (440,135) (429,976) (440,135) (449,012)    
Statement of Operations and Comprehensive Loss [Abstract]              
Research and development expenses 4,065 5,606 4,481 10,087 14,152    
Selling, general and administrative expenses 4,779 4,497 4,204 8,699 13,477    
Total operating expenses 8,844 10,103 8,685 18,786 27,629    
Operating loss (8,173) (9,486) (8,340) (17,826) (25,998)    
Net loss (8,877) (10,159) (9,000) (19,159) (28,036)    
Total other comprehensive loss $ (8,923) $ (10,190) $ (8,998) $ (19,188) $ (28,118)    
Basic loss per common share* $ 0.96 $ (1.24) $ (1.1) $ (2.34) $ (3.29)    
Diluted loss per common share* $ 0.96 $ (1.24) $ (1.1) $ (2.34) $ (3.29)    
Statement of Stockholders' Equity [Abstract]              
Compensation expense for issuance of stock options $ 1,627 $ 2,119 $ 2,271        
Net loss (8,877) (10,159) (9,000) $ (19,159) $ (28,036)    
Statement of Cash Flows [Abstract]              
Net loss $ (8,877) $ (10,159) (9,000) (19,159) (28,036)    
Stock option compensation expense     $ 2,271 $ 4,390 $ 6,016